Medco Health Solutions and Mayo Collaborative Services announced a collaboration to jointly evaluate the medical, clinical, and cost-saving potential of genetic testing, while improving patient safety and care, in the community setting.Genetic testing will be conducted in more than 1,000 patients taking warfarin from a population of more than 200,000 patients who are annually identified as new to warfarin therapy in Medco's prescription drug database. Each year, approximately 2 million people in the US begin therapy with warfarin. The program is scheduled to begin enrolling patients in the first quarter of 2007 and to be completed by the end of this year.
展开▼
机译：Medco Health Solutions和Mayo Collaborative Services宣布了一项合作项目，旨在共同评估基因检测在医学，临床和节省成本方面的潜力，同时在社区环境中改善患者的安全性和护理水平，将对1000多名服用该药物的患者进行基因检测华法林来自200,000多名患者，这些患者每年在Medco处方药数据库中被确定为华法林疗法的新成员。每年，在美国大约有200万人开始使用华法林进行治疗。该计划计划于2007年第一季度开始招募患者，并于今年年底完成。
展开▼
